HeartBeam, Inc.（BEAT）资讯与事件BEATHeartBeam, Inc.

HeartBeam Receives FDA Breakthrough Device Designation

HeartBeam announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Device Designation, BDD, for the HeartBeam System as a tool for assessing potential heart attacks at home. The FDA granted the designation within 30 days of HeartBeam's request, well ahead of the agency's 60-day statutory review period.

HeartBeam Clarifies Focus on Heart Attack Detection

HeartBeam issued a letter to shareholders from its Executive Chairman Richard Ferrari, and President and Founder, Branislav Vajdic, PhD, which read, in part, "HeartBeam is at an inflection point, and we want to be direct about what we are doing, what we are not doing, and why. We have learned a great deal from the early commercialization of our FDA-cleared arrhythmia product. The most important lesson is that scaling commercialization ourselves would require substantial capital and commercial infrastructure at a time when we believe those resources can create substantially more value elsewhere. We have therefore made a deliberate choice: we will not build a large commercial organization around the current arrhythmia indication at this stage. Instead, we are redirecting the majority of HeartBeam's financial and human resources toward what we believe is our largest value-creation opportunity: heart attack, or myocardial infarction, detection. We will continue focused, limited commercialization of our existing FDA-cleared product to generate real-world experience, support selected customers, and build relationships, but it will not be the primary driver of our spending or organization...Capital efficiency is not simply about spending less. It is about putting each dollar and each person behind the milestones we believe can create the greatest value. HeartBeam has spent more than a decade developing its 3D ECG technology, clinical foundation, and intellectual property. We believe the most valuable use of that foundation is to pursue a future capability that could help identify a suspected heart attack outside the hospital, while advancing the 12-lead patch through a capital-efficient partnering strategy. Our priorities are therefore clear: MI detection: Direct the majority of our financial and human resources to the clinical, algorithm development, and regulatory work required to support a future indication. 12-lead patch: Advance the patch toward FDA clearance while pursuing a strategic partner for commercialization. Current arrhythmia product: Continue focused, limited commercialization without building a large commercial infrastructure. Partnerships: Use partners and licensing where they can extend the reach of HeartBeam's technology more efficiently than we can on our own. We want shareholders to have no ambiguity about the direction of the Company. MI detection is our primary focus. We will advance the 12-lead patch toward FDA clearance while pursuing a strategic commercialization partner. And we will continue commercialization of our existing arrhythmia product in a focused manner without allowing it to divert substantial resources from these higher-value priorities. These are deliberate choices about where we believe HeartBeam can create the greatest value with the resources we have.